Labiotech.eu

News and Trends 11 Feb 2015

AB Science: One step further towards a cure to Alzheimer’s disease

AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), today announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of mild to moderate Alzheimer’s disease. Today, between 5 and 10 million people suffer from Alzheimer’s disease in the USA […]

February 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 10 Feb 2015

Is Pichia Pastoris the Best Protein Expression System?

Producing biologicals in living expression systems is a big challenge for the Biotech industry. World leaders in the field are betting on a new yield-enhancing expression technology using the yeast Pichia pastoris. Escherichia coli might be the first bacteria you think about when it comes to biotechnology. However, E. coli is not necessarily the best option to produce […]

February 10, 2015 - 4 minutesmins - By Lourdes Riquelme

News and Trends 7 Feb 2015

Fermentalg launch an Omega-3 enriched oil produced by microalgae

Six years after the creation of the company, Fermentalg, an industrial biotechnology company that specializes in the production of oils and proteins derived from microalgae, has received the European Novel Food authorization for its first product: DHA-enriched oil (Omega-3) for the vast human nutrition market. Obtaining this authorization means Fermentalg has achieved one of the priority […]

February 7, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 6 Feb 2015

2014, the Biggest Year Ever for European Biotech IPOs

There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom has shaken stock markets throughout 2014. For European start-ups, last year represented a remarkable step forward as 15 companies went public and raised €719.8M in total, as Biocom’s last report states. Let me present you a review summering the major […]

February 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 Feb 2015

And now, Moderna signs a strategic partnership with prestigious Institut Pasteur

Moderna is the Biotech company that raised the biggest VC round ever ($450M) and which signs deals almost every week. It signed a $50M deal with Merck two weeks ago, and now signs a strategic partnership with prestigious Institut Pasteur from Paris through its new Venture Valera. Moderna is developing a proprietary mRNA therapeutics platform. Instead […]

February 4, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Feb 2015

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools

New agreement was signed between AYOXXA, an international biotech company with headquarters in Cologne, and the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic […]

February 3, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 2 Feb 2015

Will 4D Pharma be UK’s next Microbiome leader?

4D Pharma, a biopharmaceutical company focusing on significant new therapeutic areas, plan to raise €46M to continue the development of its drugs candidates and to exploit its microbiome platform MicroRx. Will 4DPharma be the next UK’s microbiome leader? This English company, founded in early 2014, has focused its current interests solely in the microbiome field and the discovery […]

February 2, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 1 Feb 2015

Phenex sells out its main programme to Gilead

Gilead Sciences announces the acquisition of Phenex Pharmaceuticals’ development program for non-alcoholic steatohepatitis (NASH) and other liver diseases. Gilead Sciences and Phenex Pharmaceuticals announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including non-alcoholic steatohepatitis […]

February 1, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 31 Jan 2015

An Anglo-French Partnership To Cure Hepatitis B

European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. This deal grants ITS the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31 Adjuvant. Valneva’s IC31 Adjuvant is a unique synthetic adjuvant combining the immuno-stimulating properties […]

January 31, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Jan 2015

The Human Protein Atlas: exploring human geography

Some 20 years ago, before the genomic era, isolating a protein and identifying the tissue where it was present was enough to get a PhD. Swedish researchers just did it for all the proteins in the human body: the equivalent of 20,000 thesis from the pregenomic age, at a stroke. Thanks to the ‘omics’, the […]

January 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 Jan 2015

Italian Genenta Science’s Original Strategy to Treat Cancer

Tumor microenvironment, including tumor-associated macrophages, plays a key role in controlling tumor progression and response to therapies. It stimulates tumor growth, supports angiogenesis and tissue remodeling, as well as neutralizes host immunity. Genenta Science is using this mechanism, which is certainly a promising area of cancer biology for the identification of new therapeutic targets. In […]

January 27, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Jan 2015

Is Gecko’s Bio-inspired Glue going to revolutionize Heart Surgery and Tissue Repair?

Imagine you could use a glue to fix a hole or week zone inside your body. Sound promising? Definitely. A new generation of adhesive has been discovered. It can be used in a highly challenging environment and be activated by light. The illustration below shows you how it could be used in heart surgery. The […]

January 26, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

AB Science: One step further towards a cure to Alzheimer’s disease

Is Pichia Pastoris the Best Protein Expression System?

Fermentalg launch an Omega-3 enriched oil produced by microalgae

2014, the Biggest Year Ever for European Biotech IPOs

And now, Moderna signs a strategic partnership with prestigious Institut Pasteur

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools

Will 4D Pharma be UK’s next Microbiome leader?

Phenex sells out its main programme to Gilead

An Anglo-French Partnership To Cure Hepatitis B

The Human Protein Atlas: exploring human geography

Italian Genenta Science’s Original Strategy to Treat Cancer

Is Gecko’s Bio-inspired Glue going to revolutionize Heart Surgery and Tissue Repair?

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!